An Open-label Multi-center Study of Imatinib and Nilotinib in CAMN107ECN02 On-treatment Patients With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase After the End of CAMN107ECN02 Core Study
Phase of Trial: Phase III
Latest Information Update: 03 Apr 2017
At a glance
- Drugs Nilotinib (Primary) ; Imatinib
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Registrational
- Sponsors Novartis
- 29 Mar 2017 Status changed from active, no longer recruiting to completed.
- 01 Aug 2016 Planned End Date changed from 1 Jan 2016 to 1 Jan 2017.
- 01 Aug 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Jan 2017.